| Objective The present study aims to identify the efficacy and safety of long-term moderate dose rosuvastatin(20mg/d)in the elderly patients with high cardiovascular risk.Methods A total of 158 patients with dyslipidemia were selected in the center of Dalian university affiliated Zhongshan hospital from December 2013 to December2017,the level of LDL-C≥1.81 mmol/L and ≥65 years old patients with high cardiovascular risk.According to the random number table method,the patients were divided into two groups.Including control group(10mg/d)86 patients and observation group(20mg/d)72 patients.All the drugs were taken at 2h after dinner,and lasted for 36 months.All patients were taken blood before fasting for 12 hours,and the blood taken up to 5ml.The total cholesterol(TC)level was detected by cholesterol oxidase method,triglyceride(TG)level was tested by glycerol phosphate oxidase peroxidase method and the LDL-C level was evaluated by colorimetric method,respectively.Creatine kinase,serum aminotransferase(alanine aminotransferase and aspartate aminotransferase)and other indicators were detected in the Central Laboratory of our hospital by routine methods.The adverse reaction of the patients was recorded at the same time.Results 1.There was no significant difference in age,sex,body mass index,hypertension,diabetes,coronary heart disease and smoking between the two groups(P > 0.05).2.The changes of blood lipid before and after taking rosuvastatin in the two groups:Control group(rosuvastatin 10mg/d,36 months)TC: Compared with 0month,the TC level was decreased significantly after 36 months of medication(3.30±0.79 vs5.32±1.31 mmol/L,P < 0.05),reduced by 37.9%;LDL-C level: Compared with0 month,the LDL-C level was lowered significantly after 36 months of medication(2.11±0.28 vs 3.55±0.65 mmol/L,P<0.05),reduced by 40.6%;TG level: Compared with 0month,the TG level was decreased significantly after 36 months of medication(1.33±0.27 vs 1.68±0.57 mmol/L,P<0.05),reduced by 17.0%.Observation group(rosuvastatin 20mg/d,36 months)TC: Compared with0 month,the TC level was decreased significantly after 36 months of medication(2.92±0.69 vs 5.45±1.12 mmol/L,P < 0.05),reduced by 46.4%;LDL-C level:Compared with 0month,the LDL-C level was lowered significantly after 36 months of medication(1.78±0.49 vs 3.38±0.89 mmol/L,P<0.05),reduced by 47.3%;TG level: Compared with 0month,the TG level was decreased significantly after 36 months of medication(1.21±0.29 vs 1.72±0.69 mmol/L,P<0.05),reduced by 29.7%.Compared with control group,the TC level was decreased significantly in the observation group(2.92±0.69 vs 3.30±0.79 mmol/L,P<0.05),reduced by 11.5%;the LDL-C level was lowered significantly in the observation group(1.78±0.49 vs2.11±0.28 mmol/L,P < 0.05),reduced by 15.6%;the TG level was decreased significantly in the observation group(1.21±0.29 vs 1.33±0.27 mmol/L,P<0.05),reduced by 12.5%.3.The changes of creatine kinase before and after taking rosuvastatin in the two groups:Control group(rosuvastatin 10mg/d,36 months)CK level: Compared with0 month,there is no significant difference in serum CK level after 36 months of medication(89.42±39.19 vs 84.12±37.98 U/L,P > 0.05).Observation group(rosuvastatin 20mg/d,36 months)CK level: Compared with0 month,the CK level was increased slightly after 36 months of medication(90.67±42.39 vs 83.65±41.98 U/L,P > 0.05),but the difference was not statistically significant.Compared with control group,there is no significant difference in serum CK level in the observation group(90.67±42.39 vs 89.42±39.19 U/L,P>0.05).4.The changes of transaminase level before and after taking medicine in the two groups were: Control group(rosuvastatin 10mg/d,36 months)ALT level: Compared with 0month,there is no significant difference in serum CK level after 36 months of medication(26.98±7.21 vs 24.98±7.51 U/L,P>0.05);AST level: Compared with0 month,the AST level was increased slightly after 36 months of medication(28.24±6.59 vs 26.44±7.69 U/L,P>0.05),but the difference was not statistically significant.Observation group(rosuvastatin 20mg/d,36 months)ALT level: Compared with0 month,the ALT level was increased slightly after 36 months of medication(28.67±7.61 vs 26.12±6.99 U/L,P>0.05),but the difference was not statistically significant;AST level: Compared with 0month,the AST level was increased slightly after 36 months of medication(30.54±7.21 vs 27.52±8.39 U/L,P>0.05),but the difference was not statistically significant.Compared with control group,the ALT level was increased slightly in the observation group(28.67±7.61 vs 26.98±7.21,P>0.05),but the difference was not statistically significant;the AST level was increased slightly in the observation group(30.54±7.21 vs 28.24±6.59 U/L,P>0.05),but the difference was not statistically significant.Conclusion The LDL-C in the elderly patients with high cardiovascular risk reach the standard level after long term enhanced lipid treatment,and the levels of ALT,AST,CK have no further rise. |
PDF Full Text Request